Josiah Hawks

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Venues

BMC research notes

Clinical cancer research : an official journal of the American Association for Cancer Research

Huntsman Cancer Institute

Westminster College (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Huntsman Cancer Institute Nov 16 2017

United States

Data Manager :: Research Compliance Office

Education History

Westminster College

United States

MSC

Publications

Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Archana M Agarwal, Roberto H Nussenzveig, Andrew W Hahn, John M Hoffman, Kathryn Morton, Sumati Gupta, Julia Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth M Boucher, Benjamin Haaland, Benjamin L Maughan
Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (9) (2020)

Josiah Hawks.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Josiah Hawks